AI Insight
This study compared the quality of palliative care between designated and non-designated cancer hospitals in Japan, using bereaved family surveys from 27,944 participants whose relatives died in 2018. Non-designated cancer hospitals tended to serve older and less symptomatic patients, while designated cancer hospitals showed higher symptom burden scores on the Memorial Symptom Assessment Scale. Despite these differences in patient characteristics, no clinically meaningful difference in overall palliative care quality was found between the two hospital types when assessed by bereaved families, though satisfaction scores were modestly higher in non-designated hospitals.
Why it matters
Since approximately 70% of cancer deaths occur in non-designated cancer hospitals, this study provides important evidence that palliative care quality in these underexamined settings is broadly comparable to that of specialized cancer centers, which can inform healthcare policy and resource allocation decisions.
⚠️ Preprint – Noch nicht peer-reviewed
Dieser Artikel wurde noch nicht von unabhängigen Experten begutachtet. Die Ergebnisse sind vorläufig und sollten mit Vorsicht interpretiert werden.
Background: The quality of palliative care in non-designated cancer hospitals, where approximately 70% of deaths of patients with cancer occur, remains unevaluated. This study aimed to clarify the quality of palliative care in these hospitals by comparing patient characteristics and evaluating the quality of palliative care provided by bereaved families. Methods: A questionnaire survey was conducted among bereaved family members of patients with cancer who died in 2018 at designated and non-designated cancer hospitals (excluding palliative care units). We compared the two groups regarding patient and bereaved family characteristics, quality assessment of palliative care (including Memorial Symptom Assessment Scale [MSAS]), care satisfaction, and the presence of end-of-life discussions. Results: In total, 27,944 bereaved family members agreed to participate. The mean age at death was 73.2 ({+/-}11.9) and 79.7 ({+/-}10.9) years for designated and non-designated cancer hospitals, respectively (p < 0.001, Effect Size [ES] = 0.55). The mean MSAS total score (symptom intensity) was significantly higher for designated cancer hospitals than for non-designated cancer hospitals, even after adjusting for patient characteristics (p < 0.001, ES = 0.39). Conversely, the mean adjusted overall satisfaction was significantly higher in non-designated cancer hospitals (p < 0.001, ES = 0.21) than in designated cancer hospitals. Conclusions: Non-designated cancer hospitals had older and less symptomatic patients than designated cancer hospitals. However, there was no significant clinical difference in the quality of palliative care, as assessed by the bereaved families.